Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder

Report of a prospective, randomized trial

C. M. Pinsky, Fernando J. Camacho, D. Kerr, N. L. Geller, F. A. Klein, H. A. Herr, W. F. Whitmore, H. F. Oettgen

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

In an attempt to prevent, delay, or reduce further tumor occurrence, 88 patients with recurrent, superfical carcinoma of the urinary bladder were randomly assigned to receive either standard therapy (cystoscopy with fulguration) or standard therapy and bacillus Calmette-Guerin (BCG). BCG was administered intravesically and percutaneously once weekly for 6 weeks. No serious toxicity was seen. There were 43 evaluable patients in each of the two groups. Results in the BCG group versus the control group were as follows: reduction in the number of recurrent tumors (43 vs 27 patients [P < 0.001]); conversion to negative cytology (11 of 33 vs three of 34 patients [P < 0.05]; and tumor progression requiring cystectomy (three vs 15 patients [P < 0.001]). Disease-free interval (P < 0.001), time with negative cytology (P < 0.001), and time to progression of disease (P < 0.003) were longer in patients treated with BCG. These results indicate that the combination of standard therapy and BCG is more effective than standard therapy alone in patients with recurrent superficial bladder tumors.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - Mar 13 1985
Externally publishedYes

Fingerprint

Intravesical Administration
Mycobacterium bovis
Urinary Bladder
Carcinoma
Cell Biology
Neoplasms
Cystoscopy
Cystectomy
Therapeutics
Urinary Bladder Neoplasms
Disease Progression
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder : Report of a prospective, randomized trial. / Pinsky, C. M.; Camacho, Fernando J.; Kerr, D.; Geller, N. L.; Klein, F. A.; Herr, H. A.; Whitmore, W. F.; Oettgen, H. F.

In: Cancer Treatment Reports, Vol. 69, No. 1, 13.03.1985, p. 47-53.

Research output: Contribution to journalArticle

Pinsky, C. M. ; Camacho, Fernando J. ; Kerr, D. ; Geller, N. L. ; Klein, F. A. ; Herr, H. A. ; Whitmore, W. F. ; Oettgen, H. F. / Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder : Report of a prospective, randomized trial. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 1. pp. 47-53.
@article{d2a35623e3d3488997fd1ec421303998,
title = "Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial",
abstract = "In an attempt to prevent, delay, or reduce further tumor occurrence, 88 patients with recurrent, superfical carcinoma of the urinary bladder were randomly assigned to receive either standard therapy (cystoscopy with fulguration) or standard therapy and bacillus Calmette-Guerin (BCG). BCG was administered intravesically and percutaneously once weekly for 6 weeks. No serious toxicity was seen. There were 43 evaluable patients in each of the two groups. Results in the BCG group versus the control group were as follows: reduction in the number of recurrent tumors (43 vs 27 patients [P < 0.001]); conversion to negative cytology (11 of 33 vs three of 34 patients [P < 0.05]; and tumor progression requiring cystectomy (three vs 15 patients [P < 0.001]). Disease-free interval (P < 0.001), time with negative cytology (P < 0.001), and time to progression of disease (P < 0.003) were longer in patients treated with BCG. These results indicate that the combination of standard therapy and BCG is more effective than standard therapy alone in patients with recurrent superficial bladder tumors.",
author = "Pinsky, {C. M.} and Camacho, {Fernando J.} and D. Kerr and Geller, {N. L.} and Klein, {F. A.} and Herr, {H. A.} and Whitmore, {W. F.} and Oettgen, {H. F.}",
year = "1985",
month = "3",
day = "13",
language = "English (US)",
volume = "69",
pages = "47--53",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder

T2 - Report of a prospective, randomized trial

AU - Pinsky, C. M.

AU - Camacho, Fernando J.

AU - Kerr, D.

AU - Geller, N. L.

AU - Klein, F. A.

AU - Herr, H. A.

AU - Whitmore, W. F.

AU - Oettgen, H. F.

PY - 1985/3/13

Y1 - 1985/3/13

N2 - In an attempt to prevent, delay, or reduce further tumor occurrence, 88 patients with recurrent, superfical carcinoma of the urinary bladder were randomly assigned to receive either standard therapy (cystoscopy with fulguration) or standard therapy and bacillus Calmette-Guerin (BCG). BCG was administered intravesically and percutaneously once weekly for 6 weeks. No serious toxicity was seen. There were 43 evaluable patients in each of the two groups. Results in the BCG group versus the control group were as follows: reduction in the number of recurrent tumors (43 vs 27 patients [P < 0.001]); conversion to negative cytology (11 of 33 vs three of 34 patients [P < 0.05]; and tumor progression requiring cystectomy (three vs 15 patients [P < 0.001]). Disease-free interval (P < 0.001), time with negative cytology (P < 0.001), and time to progression of disease (P < 0.003) were longer in patients treated with BCG. These results indicate that the combination of standard therapy and BCG is more effective than standard therapy alone in patients with recurrent superficial bladder tumors.

AB - In an attempt to prevent, delay, or reduce further tumor occurrence, 88 patients with recurrent, superfical carcinoma of the urinary bladder were randomly assigned to receive either standard therapy (cystoscopy with fulguration) or standard therapy and bacillus Calmette-Guerin (BCG). BCG was administered intravesically and percutaneously once weekly for 6 weeks. No serious toxicity was seen. There were 43 evaluable patients in each of the two groups. Results in the BCG group versus the control group were as follows: reduction in the number of recurrent tumors (43 vs 27 patients [P < 0.001]); conversion to negative cytology (11 of 33 vs three of 34 patients [P < 0.05]; and tumor progression requiring cystectomy (three vs 15 patients [P < 0.001]). Disease-free interval (P < 0.001), time with negative cytology (P < 0.001), and time to progression of disease (P < 0.003) were longer in patients treated with BCG. These results indicate that the combination of standard therapy and BCG is more effective than standard therapy alone in patients with recurrent superficial bladder tumors.

UR - http://www.scopus.com/inward/record.url?scp=0021970625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021970625&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 47

EP - 53

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -